Mesoblast company info

What does Mesoblast do?
Mesoblast (ASX:MSB), (NASDAQ:MESO) is a biopharmaceutical company focused on developing and commercializing innovative allogeneic cellular medicines to treat severe and life-threatening conditions. The company's products are based on its proprietary mesenchymal lineage cell therapy technology, which aims to provide significant improvements for patients suffering from inflammatory ailments, cardiovascular diseases, and back pain. Mesoblast's pipeline includes several late-stage clinical candidates targeting conditions such as acute graft versus host disease, chronic heart failure, and chronic low back pain. Their objective is to harness the power of cells to regenerate tissues and organs and to provide life-changing treatments for patients who have limited options. Mesoblast is also traded on the Australian Securities Exchange (ASX:MSB), highlighting its global presence and commitment to advancing healthcare through innovative medical research.
Mesoblast company media
Company Snapshot

Is Mesoblast a public or private company?

key
Ownership
Public

How many people does Mesoblast employ?

people
Employees
83

What sector is Mesoblast in?

pie chart
Sector
Health Care

Where is the head office for Mesoblast?

location pin
Head Office
Melbourne, Australia

What year was Mesoblast founded?

founded flag
Year Founded
2004
What does Mesoblast specialise in?
/Stem Cell Therapies /Regenerative Medicine /Chronic Disease Treatment /Clinical Trials /Bone Marrow Transplants /Inflammatory Condition Management

What are the products and/or services of Mesoblast?

Overview of Mesoblast offerings
Ryoncil (remestemcel-L) for treating steroid-refractory acute graft versus host disease in children.
REVASCOR for advanced chronic heart failure treatment aiming to reduce major adverse cardiovascular events.
MPC-150-IM for reducing heart failure-related hospitalizations in patients with left ventricular systolic dysfunction.
MPC-25-IC for treating acute myocardial infarction to improve heart function.
Remestemcel-L for COVID-19 induced acute respiratory distress syndrome, aiming to improve survival in severely affected patients.
MPC-06-ID for treating chronic low back pain due to disc degeneration, focusing on reducing pain and improving function.

Who is in the executive team of Mesoblast?

Mesoblast leadership team
  • Dr. Silviu  Itescu FACP, FACRA, FRACP, MBBS (Hons)
    Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
    Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
  • Dr. Eric A. Rose M.D.
    Dr. Eric A. Rose M.D.
    Chief Medical Officer & Executive Director
  • Mr. Andrew  Chaponnel B.Com.
    Mr. Andrew Chaponnel B.Com.
    Interim Chief Finance Officer
  • Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)
    Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)
    General Counsel & Corporate Executive
  • Mr. Roger D. Brown BA
    Mr. Roger D. Brown BA
    Head of Spinal Orthopedic Disorders
  • Mr. Michael  Schuster BSc, M.B.A., MS
    Mr. Michael Schuster BSc, M.B.A., MS
    Head of Pharma Partnering
  • Ms. Geraldine  Storton B.Sc., M.B.A., MMS
    Ms. Geraldine Storton B.Sc., M.B.A., MMS
    Head of Regulatory Affairs & Quality Management
  • Mr. Justin  Horst B.S.
    Mr. Justin Horst B.S.
    Head of Manufacturing